VRNDF - Delta 9 Cannabis Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.3761
+0.0271 (+7.77%)
At close: 3:48PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.3490
Open0.3500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3500 - 0.3839
52 Week Range0.2220 - 1.0900
Volume65,695
Avg. Volume28,304
Market Cap33.525M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.1180
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Delta 9 Applauds Manitoba Retail Cannabis Expansion

      Delta 9 will be undertaking multiple expansion strategies and applying for licenses to open additional cannabis retail outlets in Manitoba, as a part of the third phase of retail cannabis expansion announced last week by the Manitoba Government. On Friday May 22, 2020, Manitoba Minister of Crown Services Jeff Wharton announced that the Manitoba Government would be moving forward on its plan for an open and competitive cannabis retail market.

    • GlobeNewswire

      Delta 9 Launches New Investor Website

      The new website, which launched today, has been designed to offer a user-friendly experience with improved navigation and functionality that allows investors to better understand the three pillars of Delta 9’s business. Created with the user experience in mind, the site includes many new features to help users quickly and easily navigate the site and learn about Delta 9’s corporate strategy to diversify risk with its three separate business units. “Investors now have all of Delta 9’s corporate, financial, and investment information at their fingertips.”

    • GlobeNewswire

      Delta 9 Reports Record First Quarter 2020 Results

      WINNIPEG, Manitoba, May 14, 2020 -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the.

    • CNW Group

      C-Suite At The Open: John Arbuthnot, Co-Founder,CEO & Director, Delta 9 Cannabis tells his Company Story. Filmed on April 30, 2020

      C-Suite At The Open: John Arbuthnot, Co-Founder,CEO & Director, Delta 9 Cannabis tells his Company Story. Filmed on April 30, 2020

    • GlobeNewswire

      Delta 9 Provides Guidance & Timing for Q1 2020 Results

      The Company anticipates direct cannabis production cost per gram of $0.98 and total cost per gram of $1.10 for the first quarter 2020, compared with $0.91 and $1.04 respectively for the fourth quarter of 2019. Delta 9 anticipates total grams of cannabis produced of 1,198,983 for the first quarter of 2020, compared with 1,305,806 grams of cannabis for the fourth quarter 2019. “We are anticipating a continuation of strong year-over-year and sequential results for the first quarter of this year,” said John Arbuthnot, CEO of Delta 9.

    • Did You Manage To Avoid Delta 9 Cannabis' (TSE:DN) Devastating 72% Share Price Drop?
      Simply Wall St.

      Did You Manage To Avoid Delta 9 Cannabis' (TSE:DN) Devastating 72% Share Price Drop?

      Even the best investor on earth makes unsuccessful investments. But it's not unreasonable to try to avoid truly...

    • GlobeNewswire

      Delta 9 Receives Approval from Health Canada for Expansion to Processing Area

      The Company anticipates that once the processing center is operating at capacity it will allow for processing of up to 25,000 kg/year of dried cannabis flower material. “The excess capacity in the new production line will also allow us to source premium cannabis flower from other licensed producers, including the Company’s micro-cultivation partners, for sale through our wholesale and retail distribution network.”

    • GlobeNewswire

      Delta 9 Achieves Milestone in Agreement with another Micro Cultivation Partner  

      Cypress Craft is an arms length third party in which the Company has no ownership control or interest. As one of the Company’s micro cultivation partners, Cypress Craft, entered into a Strategic Cooperation Agreement (“SCA”) with Delta 9 whereby Delta 9 provides services relating to the cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada license.

    • GlobeNewswire

      Delta 9 Implements Health and Safety Precautions, Maintains Operations Amid COVID-19 Outbreak

      To date the Company has been able to maintain continuous operations of its retail stores, wholesale and business to business (“B2B”) business units and has no current plans to shut down its businesses. Management continues to focus on maintaining continuity of business while implementing certain policies and procedures to protect the health and safety of our customers and employees.

    • ACCESSWIRE

      Delta 9 Cannabis, Inc. to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / March 20, 2020 / Delta 9 Cannabis, Inc. (OTCMKTS:VRNDF) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 20, 2020 at ...

    • GlobeNewswire

      Delta 9 Reports Year End and Q4 2019 Results

      WINNIPEG, Manitoba, March 19, 2020 -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for.

    • GlobeNewswire

      Delta 9 Provides Guidance & Timing for Year End Results

      The Company anticipates revenues for the year ending December 31, 2019 to be between $31.1 million and $31.9 million, compared to $7.57 million for the same period the prior year. The Company anticipates reporting direct cannabis production cost per gram of $0.91 and total cost per gram of $1.04 for the fourth quarter 2019, compared with $1.08 and $1.21 respectively for the third quarter of 2019. Delta 9 anticipates reporting total grams of cannabis produced of 1,305,806 for the fourth quarter of 2019, compared with 871,517 grams of cannabis for the third quarter 2019.

    • THCP, The New Cannabinoid Said To Be 30x Stronger Than THC: But What Does This Actually Mean?
      Benzinga

      THCP, The New Cannabinoid Said To Be 30x Stronger Than THC: But What Does This Actually Mean?

      Article originally posted on Confident Cannabis, shared with Benzinga Cannabis.Word of a new form of THC (THCP) hit the mainstream media last month and exploded into frenzied hoopla that a cannabinoid 30-times stronger than anything seen before was coming to the market. While there was indeed a new cannabinoid discovered by Italian scientists, with a stronger affinity for binding to the receptors of the brain, there is so much more to the story about this initial finding. So we reached out to Ben Armstrong with Juniper Analytics to help us sift through the report and understand the science behind this study. It is of note that Ben has read the paper, and knows the background science of isolating cannabinoids for research, but did not directly conduct this research. However, he did offer some insight into what this new information means.The Structure of a THC Molecule, THCPFirst, we begin with a little background on the study submitted by an Italian research group with members from the National Council of Research, among other groups. The most interesting finding- that has everyone buzzing is the discovery of a new form of THC--dubbed Delta-9 THCP-- a phytocannabinoid with a 7-chain carbon atom tail and its influences on biological activity. Up to this point, scientists thought only cannabinoids with a 5-atom chain were naturally occurring.Ben explained that essentially THCP mimics the same molecular properties as Delta-9 THC, but the extended tail gives the molecule a greater affinity for bonding with the CB1 and CB2 receptors. However, binding with more affinity does not mean the molecule causes stronger effects. THC molecule, U.S. Institute of Medicine, March 1999On the right side of the currently known THC molecule there is a crooked tail with five points after the rings, each one representing a carbon atom. The hypothesis is that THCP, with seven carbons, will bind much more tightly (with a greater affinity) than the one with only five carbons. The term binding affinity is widely used in molecular sciences--particularly to define the potency of drugs--as a description of anything that binds to a brain receptor giving scientists a unit of measurement for the prevalence of attraction between the two. Ben urges that this term takes into account many more factors than just how strong the molecule connects to the brain.See Also: New Cannabis Products: High-CBD Gummies, Sparkling Water, And Two Recovery Options"Theoretically, the more affinity, the smaller amount of medication needed to solicit effects, but we don't know if that's the case here," he said.That is precisely the rabbit hole that many in the media are going down to claim that this could be a much stronger THC, but we don't necessarily know that. According to Ben, all we know is that it bonds better. While a striking discovery, this doesn't necessarily indicate that someone would get a 30x more intense psychotropic effect (what recreational consumers would call "The High") in the brain.What takes place within that bond is not something that Ben is an expert on, and something that scientists are still studying to figure out. Researchers have identified nearly 150 different cannabinoids, each having its own binding affinity. Many cannabinoids have known psychoactive effects, in that they bind to a receptor, but not necessarily a psychotropic effect that induces a high, which is why it's great to see a group on the other side of the world putting time and resources into finding these answers."What those affinities are and how they influence the downstream effects is not super well known at this point," he said. "A respected journal getting a lot of media attention on cannabis is how we are going to answer these questions as to what cannabinoids are out there, how they bind to these receptors, and whether they elicit psychoactive versus psychotropic effects."How Scientists Isolated this New CompoundAccording to the paper, scientists took an ethanol extract of the strain FM2 provided by the Italian Military Chemical Pharmaceutical Institute and put it in a liquid chromatography system coupled to a high-resolution Orbitrap Mass Spectrometer, which for people familiar with the science means they used this system to separate and analyze the extract.Not a chemistry expert? Ben put it this way: Say you have a bag of Skittles with all the colors of the rainbow and you want to study the molecules of the green ones versus the red. This machine is going to separate those little candies based on color, diluting the green ones first, then the red, then the orange ones so you have them all divided out by color. Then the high-resolution Mass Spec uses extremely complicated chemistry to look at what the molecules are composed of, and what parts show up in the fragmentation patterns, by blasting everything apart to differentiate that the green Skittle has this stuff going on and the red Skittle has that other stuff happening. Scientists involved in this study were able to show precursor ions for THCP, fragments that had not been identified in other cannabinoids previously.Specific Physical EffectsSome members of the cannabis industry speculate that this could be the start of isolating cannabinoids for specific physical effects, but that's a slippery slope, says Ben. He doesn't necessarily disagree with the statement, but we don't know for sure at this point where this information will lead. People are already extracting cannabinoids for specific uses, as seen in the hemp industry with CBD extracts. With exceptional techniques, one could isolate THCP from the other cannabinoids, but that shrinks the full picture of what cannabis molecules can do collectively."There are now well over 100 identified cannabinoids, and people should be interested in talking about the Entourage Effect that comes from the combination of these compounds," Ben said. "There are a lot of important interactions that take place between the cannabinoids, terpenes, and other compounds in cannabis all working synergistically to elicit molecular effects in the body."What Happens NextAbove all, Ben says this certainly begs the question as to whether THCP is present in other strains beyond just the one tested in Italy."If I had to guess THCP is in many varieties out there and it could help to explain some of the psychotropic effects people get from strains that may not be attributed to just the level of THC," he said. "Is Delta-9 THCP present in other cultivars of cannabis that we see on a regular basis here in Oregon, California, or Washington? If not, why? If so, how?"See Also: Confident Cannabis And The Road To Transparency In The IndustryBen believes one of the next steps should be comparing this Delta-9 THCP to traditional THC for its dose-dependent effects."How do you measure someone's high? You need a metric. In the paper, they use locomotion, meaning if you're high you're not going to move around as much," he said. "It would be interesting to look at the effects of THCP versus Delta-9 THC. That would at least tell us if they see 30-times greater hypo-locomotion or other events in the test subject."What's Really The Big Deal Here?Of course, it's exciting to see a new naturally occurring cannabinoid identified, but Ben thinks there is a more significant win here."This finding is a big deal to me and others in the industry because it shows there are academic groups around the world working on isolating and understanding the in-vitro and in-vivo activity that cannabinoids and other molecules in cannabis contain," he said. "A lot of us have hoped for these studies because we're decades behind in the molecular understanding of cannabis."Scientists have conducted reputable research studies for tons of plants, pharmaceuticals, and other medicinal compounds, so to see groups start to take on these questions about cannabis is the crucial part that all of us should take out of this study."It's exciting to see a major scientific research report on cannabinoids in a top academic journal that has been peer-reviewed and accepted by a group of experts in molecular biology," Ben concluded. "Researchers will not make this claim lightly, which holds a level of authority over people writing whatever they want and posting it to Google."The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.See more from Benzinga * Double-Edged Sword: The SAFE Banking Act's Medical Cannabis Solutions May Create New Problems * Entering The New Age Of Sustainable Cannabis Startups * Cannabis And Social Equity: Challenges And Opportunities(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • GlobeNewswire

      Delta 9 Announces Continued Strategic Partnership and 2.0 Cannabis Product Supply Agreement with Auxly

      DELTA 9 CANNABIS INC. (DN.TO) (VRNDF) ("Delta 9" or the "Company"), is pleased to announce that it has entered into a supply agreement with Auxly Cannabis Group Inc. (XLY.V) ("Auxly") who will supply Delta 9's retail stores with a suite of cannabis 2.0 products including cannabis oils, chocolates, chewables and vape products, where permitted. Auxly and Delta 9 entered a strategic partnership in September, 2018, including a supply agreement which granted Auxly the right to purchase up to 5,000 kilograms of cannabis and 500 kilograms of cannabis trim per year until July 1, 2030. In exchange, Auxly invested $16.25 million in the Company by purchasing 5,909,090 common shares of the Company, becoming one of Delta 9's early strategic investors.

    • GlobeNewswire

      Delta 9 Achieves Milestone in Agreement with Micro Cultivation Partner

      As one of the Company's micro cultivation partners, Because You Cann entered into a Strategic Cooperation Agreement (“SCA”) with Delta 9 whereby Delta 9 provides services relating to cannabis production facility design and construction, development of standard operating procedures and sanitation programs, consulting on Health Canada licensing, and other services supporting the acquisition of the Health Canada Licence. On February 7, 2020, Because You Cann Inc., confirmed it has reached its final milestone under the SCA and has been granted a cannabis micro cultivation license from Health Canada (the "Health Canada Licence").

    • Can Delta 9 Cannabis Inc. (TSE:DN) Maintain Its Strong Returns?
      Simply Wall St.

      Can Delta 9 Cannabis Inc. (TSE:DN) Maintain Its Strong Returns?

      While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

    • GlobeNewswire

      Delta 9 Update on Production and Wholesale Activities

      Over 2019, Delta 9 worked to increase its dried cannabis production capacity at its Winnipeg based facilities (the “Delta Facility”) and to add provincial listing and supply agreements to increase its distribution capacity. Delta 9’s proprietary cannabis production methodology is based around a modular, scalable, and stackable production unit called the “Grow Pod”. Over the year, the Company received several licensing approvals from Health Canada, which increased the overall number of Grow Pods licensed as at December 31, 2019, to 297, an increase in licensed capacity of 93% from 154 as at December 31, 2018.

    • GlobeNewswire

      Delta 9 Update on Business to Business Activities

      During 2019, the Company invested in creating a stand-alone business unit for its B2B activities and has cultivated relationships across Canada. For the year ending December 31, 2019, Delta 9 received orders for 89 Grow Pods versus orders for 6 Grow Pods for the year ending December 31, 2018.

    • GlobeNewswire

      Delta 9 Update on Cannabis 2.0

      Delta 9 was among the first retailers in Canada to sell edibles, vape pens, and vape cartages in its retail stores. The company received its first shipment on Wednesday, December 18, 2019 and additional shipments have arrived everyday since.

    • GlobeNewswire

      Delta 9 Receives Extract Sales Authorization from Health Canada

      WINNIPEG, Manitoba, Dec. 06, 2019 -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce that on December 4, 2019 it received an.

    • GlobeNewswire

      Delta 9 Receives Expansion Approval from Health Canada for 95 Additional Grow Areas, Provides Expansion Update

      Delta 9’s proprietary cannabis production methodology is based around a modular, scalable, and stackable production unit. The Company is now working to place the 93 flowering Grow Pods and two support Grow Pods into production which will increase production capacity by 56% and bring the total number of Grow Pods approved by Health Canada and in production to 297. The Company anticipates that these additional Grow Pods will add an additional 2,975 kg/year in dried cannabis flower production, bringing Delta 9’s overall anticipated production capacity to 8,325 kg/year.

    • GlobeNewswire

      Delta 9 Enters Definitive Agreement to Acquire Two Alberta Retail Stores

      The acquisition will be completed through the Company’s wholly-owned subsidiary, Delta 9 Cannabis Store Inc. Kronos Capital Partners acted as Financial Advisor to the Modern Leaf Group on the transaction. "We are pleased to have reached definitive agreements with Modern Leaf on this previously announced transaction," said John Arbuthnot, founder and CEO of Delta 9. The purchase price for the Proposed Transaction is $1,300,000, subject to customary adjustments (the "Purchase Price").

    • GlobeNewswire

      Delta 9 Reports Financials for Q3 2019 and Announces Grant of Stock Options

      WINNIPEG, Manitoba, Nov. 13, 2019 -- DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the.

    • GlobeNewswire

      Delta 9 Provides Guidance for Upcoming Q3, 2019 Results, Releases Date and Time for Conference Call

      Delta 9 anticipates revenues for the three-month period ending September 30, 2019 to be between $6.3 million and $6.9 million compared with $1.25 million for the three-month period ending September 30, 2018.

    • Westleaf Receives First White Label Order For Vape Pens
      CNW Group

      Westleaf Receives First White Label Order For Vape Pens

      CALGARY , Nov. 4, 2019 /CNW/ - Westleaf Inc. (the "Company" or "Westleaf") (WL.V) (WSLFF) is pleased to announce that the conditions precedent to the white-label cannabis derivative product sale agreement (the "White-Label Agreement") between the Company's wholly owned subsidiary Westleaf Labs LP ("Westleaf Labs") and Delta 9 Cannabis Inc. (NINE.V) (VRNDF) ("Delta 9") have been completed, and Westleaf Labs has received the first order from Delta 9 for an initial three-month supply of vape pens and cartridges. This first order represents anticipated revenue of ~$740,000 starting as early as January 2020 .